| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
UCF-101 (UCF101) is a novel and potent inhibitor of the pro-apoptotic mitochondrial serine protease Omi/HtrA2, which are involved in the cellular response to thermal and oxidative stress.
| ln Vitro |
MBP-Omi-(134-458)'s ability to modulate proteins is inhibited by Ucf-101 (20-100 μM; 30 min) [1]. His-Omi-(134-458) and β-casein test inhibition with His Ucf-101 (1-25 μM; 36 hours) The concentration adjustment approach inhibits His-Omi-(134-458) activity [1]. Ucf-101 (10-100 μM; 30 min) Adjust 10 min. Fibroblast cell disinfection that is dependent on caspase is negated by induction of the cytokine caspase-9 (-/-) [1]. At low doses (2.5 μM), Ucf-101 (1 – 20 μM; depletion in 1 hour) inhibits 6-OHDA-induced Parkinson’s disease (PD)–PC12 cells, while at high concentrations (≥10 μM), it increases cell fluorescence[3]. Ucf-101 (2.5 μM; sham 1 hour) Expression of C/EBP homologous protein (CHOP) and liposome regulatory protein 78 (Bip/Grp78) in PD-PC12 cells [3].
|
|---|---|
| ln Vivo |
Ucf-101 (0.6-1.8 μMol/kg; a single ip) reduces myocardial infarct size [2]. Ucf-101 (1.5 μMol/kg; a single ip) improves APO induction in an
|
| Animal Protocol |
Animal/Disease Models: Myocardial ischemia/reperfusion (MI/R) injury in adult male mice (20-25 g) [1]
Doses: 0.6 spin behavior, increase positive cells and reverse the decrease of PD DA neurons [3]. , 1.5, 1.8 μmol/kg Route of Administration: intraperitoneal (ip) injection 10 minutes before reperfusion Experimental Results: Terminal dUTP nick end labeling staining, DNA ladder breakage incidence and infarct size reduction. |
| References |
|
| Molecular Formula |
C27H17N3O5S
|
|---|---|
| Molecular Weight |
495.5
|
| Exact Mass |
497.104
|
| CAS # |
313649-08-0
|
| PubChem CID |
1102771
|
| Appearance |
Orange to red solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
708.4±70.0 °C at 760 mmHg
|
| Flash Point |
382.3±35.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.800
|
| LogP |
5.07
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
36
|
| Complexity |
864
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NVNSXBXKNMWKEJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H17N3O5S/c31-25-22(17-20-15-16-24(35-20)21-13-7-8-14-23(21)30(33)34)26(32)29(19-11-5-2-6-12-19)27(36)28(25)18-9-3-1-4-10-18/h1-17H
|
| Chemical Name |
5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]-1,3-diphenyl-2-sulfanylidene-1,3-diazinane-4,6-dione
|
| Synonyms |
UCF101 UCF 101 UCF-101
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~25.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.79 mg/mL (3.61 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 17.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 1.67 mg/mL (3.37 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0182 mL | 10.0908 mL | 20.1816 mL | |
| 5 mM | 0.4036 mL | 2.0182 mL | 4.0363 mL | |
| 10 mM | 0.2018 mL | 1.0091 mL | 2.0182 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
